AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q115525

Appln. No.: 10/535,341

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1. (Currently Amended) An Fc fragment as a drug carrier, which is an IgG Fc,

wherein the Fc fragment is covalently linked to a drug through a non-peptide linker, wherein the

non-peptide linker is polypropylene glycol, copolymers of ethylene glycol and propylene glycol,

polyoxyethylated polyols, polyvinyl alcohol, dextran, polyvinyl ether, polylactic acid (PLA),

polylactic- glycolic acid (PLGA), a lipid polymer, a chitin, or hyaluronic acid.

2. (Original) The Fc fragment as set forth in claim 1, wherein the IgG is IgG2 or

IgG4.

3. (Original) The Fc fragment as set forth in claim 2, wherein the IgG is IgG4.

4. (Original) The Fc fragment as set forth in claim 1, which is aglycosylated.

5. (Original) The Fc fragment as set forth in claim 4, which is an aglycosylated IgG4

Fc fragment.

6. (Previously Presented) The Fc fragment as set forth in claim 5, wherein the

aglycosylated IgG4 Fc fragment is a recombinant human IgG4 Fc fragment.

2

- 7. (Previously Presented) The Fc fragment as set forth in claim 1, which comprises an amino acid sequence that is identical to the sequence set forth in SEQ ID NO. 8, 10 or 23.
 - 8. (Withdrawn) A gene encoding the Fc fragment of claim 1.
- 9. (Withdrawn) The gene as set forth in claim 8, which has a nucleotide sequence represented by SEQ ID NO. 4, 9 or 22.
- 10. (Withdrawn) A recombinant vector comprising the nucleotide sequence of claim9.
- 11. (Withdrawn) A transformant transformed with the recombinant vector of claim10.
- 12. (Withdrawn) A method of preparing an Fc fragment, comprising culturing the transformed microorganism of claim 11.
 - 13. (Previously Presented) A composition comprising the Fc fragment of claim 1.
 - 14-15. (Canceled)

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q115525

Appln. No.: 10/535,341

16. (Currently Amended) An IgG Fc fragment as a drug carrier, the IgG Fc fragment being covalently linked to a drug through a non-peptide linker, wherein the non-peptide linker is a polyethylene polyethylene glycol having a molecular weight of 3.4 kDa [[-]] or 10 kDa.